Biodius

Scientific diligence / Falsification first

Try to kill your target before you fund the next expensive step.

Biodius helps biotech teams and investors stress-test biological targets and mechanisms before committing to the next expensive step.

Start a Target ChallengeRead the preprint →

Try to break the story.

Collapse non-independent studies. Surface contradictions and failed programmes. Challenge causal-gene and novelty claims. Identify the cheapest evidence that would actually change the decision.

A schematic: freeze the question, challenge the evidence, adjudicate against primary sources, then record ADVANCE, REWORK, STOP or NOT_EVALUABLE. 01 / FreezeQuestion + stop rule02 / ChallengeEvidence + causal chain03 / AdjudicatePrimary sourcesRecord what survives — or cannot be decided.
Method schematic · An explicit decision, including NOT_EVALUABLE.
Follow the full method →

For biotech teams

Before committing to a costly next step on a target or mechanism.

For investors

An independent, adversarial read of the biology behind an asset before a funding decision.

Four experiments. Including the uncomfortable results.

Our own prospective tests retained negative, contradictory and not-evaluable outcomes. They do not establish a therapeutic target or clinical mechanism.

Technical report; not peer reviewed. The method has not been externally validated.

Read the evidence and its limits →

Experimental by design. Bounded in scope.

Biodius is experimental scientific diligence / falsification tooling. It is not a clinical system, a therapeutic recommendation engine, a validated drug-discovery platform, a substitute for qualified scientific judgment, or proof that any biological target is causal, safe or effective.

Biodius does not provide clinical advice, validate safety or efficacy, perform wet-lab work, or replace legal, patent or regulatory review.